The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma.
AEZS-108 (AN-152/Zoptarelin Doxorubicin Acetate)
MASPIN/SERPINB5
angiogenesis
luteinizing hormone-releasing hormone (LHRH) receptor
uveal melanoma
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
14 Jan 2020
14 Jan 2020
Historique:
received:
05
12
2019
accepted:
29
12
2019
entrez:
4
2
2020
pubmed:
6
2
2020
medline:
6
2
2020
Statut:
epublish
Résumé
Uveal melanoma (UM) is the most common malignant tumor of the eye. Recently, we have established that 46% of UM specimens express LHRH receptors. This finding supports the idea of a LHRH receptor-targeted therapy of UM patients. Cytotoxic analog of LHRH, AEZS-108 exhibits effective anti-cancer activity in LHRH-receptor positive cancers. AEZS-108 is a hybrid molecule, composed of a synthetic peptide carrier and the cytotoxic doxorubicin (DOX). In the present study, we investigated AEZS-108 induced cytotoxicity and the altered mRNA expression profile of regulatory factors related to angiogenesis and metastasis in LHRH receptor positive OCM3 cells. Our results show that AEZS-108 upregulates the expression of
Identifiants
pubmed: 32010430
doi: 10.18632/oncotarget.27431
pii: 27431
pmc: PMC6968782
doi:
Types de publication
Journal Article
Langues
eng
Pagination
175-187Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Dr. A.V. Schally is listed as a co-inventor on the patents of Tulane University on AEZS-108. All authors declare no conflicts of interest.
Références
Prostate. 2011 May 15;71(7):736-47
pubmed: 20945403
Onco Targets Ther. 2018 Feb 22;11:933-941
pubmed: 29503568
Cancer Treat Rev. 2008 May;34(3):247-58
pubmed: 18226859
Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7269-73
pubmed: 8692981
BJU Int. 2013 Jun;111(7):1021-30
pubmed: 23418666
Oncotarget. 2013 Mar;4(3):422-32
pubmed: 23518876
Cancer Res. 2003 Mar 1;63(5):1138-43
pubmed: 12615733
Biomed Khim. 2016 Mar;62(3):306-10
pubmed: 27420624
Eur J Pharm Sci. 2018 Oct 15;123:371-376
pubmed: 30076951
BMC Cancer. 2014 Nov 19;14:847
pubmed: 25410881
Int J Pancreatol. 1991 Oct;10(2):151-9
pubmed: 1660910
Methods Enzymol. 2009;463:73-95
pubmed: 19892168
Dermatol Res Pract. 2010;2010:360136
pubmed: 20631901
Gynecol Oncol. 2014 Jun;133(3):427-32
pubmed: 24713545
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
J Urol. 2000 Feb;163(2):623-9
pubmed: 10647698
Curr Drug Deliv. 2011 Jan;8(1):11-25
pubmed: 21034424
Oncotarget. 2012 Jul;3(7):686-99
pubmed: 22824624
Nat Rev Mol Cell Biol. 2010 Jan;11(1):23-36
pubmed: 20027185
Curr Opin Urol. 2013 Jan;23(1):17-24
pubmed: 23202285
J Biomol Tech. 2011 Apr;22(1):37-44
pubmed: 21455480
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3742-8
pubmed: 14506166
Clin Cancer Res. 2014 Dec 15;20(24):6277-83
pubmed: 25278449
Eur J Endocrinol. 1999 Jul;141(1):1-14
pubmed: 10407215
Clin Ophthalmol. 2013;7:1669-82
pubmed: 24003303
Cancers (Basel). 2019 Jun 18;11(6):null
pubmed: 31216772
Am J Obstet Gynecol. 2002 Feb;186(2):171-9
pubmed: 11854630
Curr Drug Targets. 2016;17(5):488-94
pubmed: 26951061
Prostate. 2013 Jun;73(8):873-83
pubmed: 23280565
Int J Oncol. 2009 Oct;35(4):789-96
pubmed: 19724914
Expert Opin Investig Drugs. 2012 Jun;21(6):891-9
pubmed: 22577891
Cancers (Basel). 2019 Jun 17;11(6):null
pubmed: 31212986
J Urol. 2012 Apr;187(4):1498-504
pubmed: 22341819
Breast Cancer Res Treat. 1993;25(1):37-46
pubmed: 8390871
Cancer Res Treat. 2010 Mar;42(1):42-7
pubmed: 20369051
Cancer. 1994 Nov 1;74(9):2555-61
pubmed: 7522953
World J Gastroenterol. 2014 May 28;20(20):6102-12
pubmed: 24876732
Am J Ophthalmol. 2009 Jul;148(1):119-27
pubmed: 19375060
Cancer. 2003 Jan 15;97(2):465-75
pubmed: 12518371
Cancer Treat Rev. 2005 Aug;31(5):361-79
pubmed: 15994016
Gynecol Oncol. 2010 Dec;119(3):457-61
pubmed: 20828803
Urol Int. 2008;80(4):431-8
pubmed: 18587256
Pigment Cell Melanoma Res. 2015 Mar;28(2):135-47
pubmed: 25113308
Oncotarget. 2014 Jun 30;5(12):4567-78
pubmed: 24994120
Endocr Relat Cancer. 2004 Dec;11(4):725-48
pubmed: 15613448
Verh Dtsch Ges Pathol. 2006;90:186-92
pubmed: 17867596
Oncotarget. 2016 Feb 16;7(7):7816-28
pubmed: 26761211
Dev Ophthalmol. 2012;49:166-181
pubmed: 22042020
Prostate. 2001 Jun 1;47(4):276-84
pubmed: 11398175
Br J Cancer. 2010 Jul 27;103(3):285-90
pubmed: 20661247
Cancers (Basel). 2019 Jul 13;11(7):null
pubmed: 31337000
Trends Endocrinol Metab. 2004 Sep;15(7):300-10
pubmed: 15350601
Prostate. 1999 May;39(2):101-7
pubmed: 10221565
Oncotarget. 2013 Oct;4(10):1721-8
pubmed: 24077773